drugset / Trial / NCT01267448
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
RandomizedParallel-groupOpen-labelTreatment
Summary
Saxagliptin + Metformin XR (S+M) will be effective in stabilizing blood glucose (BG) levels in patients with newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia (BG levels 300 to 450 mg/dl) and glucose toxicity and with no criteria for inpatient admission or occurrence of severe hypoglycemia compared to glipizide XL. The study may provide preliminary evidence to support the role of S+M as a bridging, stabilizing and safe therapy in patients with severe hyperglycemia
Timeline
- Start
- 2014-09-09
- Primary completion
- 2015-07-25
- Completion
- 2015-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glipizide | Small molecule | 10 mg | Oral |
| Comparator | Metformin | Small molecule | 2000 mg | — |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | — |